Global NewsNewsPeople

Parexel ropes in Peyton Howell as CEO effective May 15, 2024

Chief Operating & Growth Officer Peyton Howell to succeed Jamie Macdonald

Parexel providing the full range of Phase I to IV clinical development services, announced that Jamie Macdonald will retire and transition his role as Chief Executive Officer (CEO) to the company’s Chief Operating and Growth Officer Peyton Howell effective May 15, 2024. 

Howell, who joined Parexel in 2018 as Chief Commercial and Strategy Officer, will be appointed to the company’s Board of Directors on May 15. Macdonald will continue on the Board through December 31, 2024, and will remain an industry advisor to EQT and the largest individual investor in Parexel.

“On behalf of EQT, Goldman Sachs Asset Management and the Parexel Board of Directors, I want to congratulate Peyton and thank Jamie for his contributions and outstanding leadership over the past six years,” said Sheri McCoy, Chairperson of the Board. “Jamie guided Parexel through a pivotal time in the company’s evolution, leading it through its successful acquisition by EQT and Goldman Sachs Asset Management in 2021 and achieving industry-leading profit growth across his tenure with the company — outpacing the top-tier CROs during this same period to position Parexel for sustainable growth.” 

She continued, “Howell is a proven strategic leader and strong successor to carry Parexel forward into its next chapter. Her deep understanding of the industry, unmatched energy passion for improving patient lives and commitment to creating value for shareholders, customers and colleagues make her the ideal candidate to lead Parexel through this exciting next phase. Together, she and Jamie have worked to ensure Parexel is well positioned for the future.” 

“It’s been a privilege to lead Parexel during this critical period in the company’s strategic transformation,” said CEO Jamie Macdonald. “Our commitment and focus on the patient have continued to differentiate Parexel, drive our focus on innovation and ultimately strengthen our ability to develop new therapies that enhance and save patient lives. We have an incredibly talented team and leader in Peyton as our next CEO.” 

He continued, “On a personal note, I’m proud of my time with Parexel and to have been part of the CRO industry for 30 years. With the company well positioned for growth, now is the right time for me to retire and spend more time with my family. Following the transition, I look forward to continuing to support Parexel as a Board member and remaining an investor. I’m truly grateful for my time with this amazing organization and to have been part of such an incredible team.” 

“I’m honoured to serve as the next CEO of Parexel,” said Howell. “With a focus on the patient, a commitment to our customers and the CRO industry’s best colleagues, we have an exciting future ahead. I’m proud of our growth and accomplishments and look forward to working with Jamie on the transition and with the Board and our leadership team to build on this momentum as we execute on our strategic initiatives, continue profitable growth and generate value for our stakeholders.” 

As Chief Operating and Growth Officer for Parexel since 2022, Howell has led the integration and alignment of all aspects of strategy, sales and delivery across the organization to better meet customer needs, build repeat business and lead the market in the next phase of drug development transformation. From 2018 to 2022 she served as Chief Commercial and Strategy Officer, implementing the company’s patient-focused strategy and launching its Biotech business unit in January 2019, which has grown by more than double. Also during her tenure, Howell has made a significant impact in growing the company’s customer relationships, delivering consistent, strong growth in gross new business awards during a period of significant volatility in the life sciences industry. 

Her 30+ year career in the healthcare industry includes senior leadership positions with AmerisourceBergen (now Cencora), a Fortune 20 company, most recently as President for Health Systems and Specialty Care Solutions, a $50 billion business unit. Before AmerisourceBergen, Howell was a founder of Lash Group, growing the company from an early innovator of patient access services to nearly 5,000 employees and serving as President for nearly 10 years following its acquisition by AmerisourceBergen. 

Howell serves on the Board of Directors of Tandem Diabetes Care, a medical device manufacturer. She holds a master’s in healthcare administration (MHA) from Ohio State University and in 2020 was named a Luminary by the Healthcare Businesswomen’s Association (HBA).

 

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Back to top button
Close
Close